New drug combo shows promise for Hard-to-Treat cancers
Disease control
Completed
This study tested a new drug called LM-108, alone or with an anti-PD-1 antibody, in 78 adults with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety and find the right dose. Early results focus on controlling tumor growt…
Phase: PHASE1, PHASE2 • Sponsor: LaNova Australia Pty Limited • Aim: Disease control
Last updated May 06, 2026 16:02 UTC